228 related articles for article (PubMed ID: 17267922)
1. Regulatory policies on medicines for psychiatric disorders: is Europe on target?
Barbui C; Garattini S
Br J Psychiatry; 2007 Feb; 190():91-3. PubMed ID: 17267922
[TBL] [Abstract][Full Text] [Related]
2. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
3. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
Dejas-Eckertz P; Schäffner G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
[TBL] [Abstract][Full Text] [Related]
4. Typical pitfalls in applications for marketing authorization of biotechnological products in Europe.
Schneider CK; Schäffner-Dallmann G
Nat Rev Drug Discov; 2008 Nov; 7(11):893-9. PubMed ID: 18974748
[TBL] [Abstract][Full Text] [Related]
5. Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years.
Ceci A; Felisi M; Baiardi P; Bonifazi F; Catapano M; Giaquinto C; Nicolosi A; Sturkenboom M; Neubert A; Wong I
Eur J Clin Pharmacol; 2006 Nov; 62(11):947-52. PubMed ID: 17021892
[TBL] [Abstract][Full Text] [Related]
6. Europe learns from US drug mistakes.
Alcorn K
J Int Assoc Physicians AIDS Care; 1996 Mar; 2(3):39. PubMed ID: 11363346
[TBL] [Abstract][Full Text] [Related]
7. Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance.
Permanand G; Mossialos E; McKee M
Clin Med (Lond); 2006; 6(1):87-90. PubMed ID: 16521363
[TBL] [Abstract][Full Text] [Related]
8. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
9. [A systemic review of the European Agency for the evaluation of medicinal products (EMEA) recommendations on the conduct of clinical trials in psychiatry].
Guaiana G; Barbui C
Epidemiol Psichiatr Soc; 2002; 11(1):28-34. PubMed ID: 12043431
[TBL] [Abstract][Full Text] [Related]
10. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials.
Marchetti S; Schellens JH
Br J Cancer; 2007 Sep; 97(5):577-81. PubMed ID: 17726450
[TBL] [Abstract][Full Text] [Related]
11. [The regulatory framework for complementary and alternative medicines in Europe].
Knöss W; Stolte F; Reh K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
[TBL] [Abstract][Full Text] [Related]
12. [European Agency for the Evaluation of Medicinal Products: five years experience].
Sauer F
Bull Mem Acad R Med Belg; 2000; 155(5-6):254-8; discussion 259-62. PubMed ID: 11304960
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency.
Regnstrom J; Koenig F; Aronsson B; Reimer T; Svendsen K; Tsigkos S; Flamion B; Eichler HG; Vamvakas S
Eur J Clin Pharmacol; 2010 Jan; 66(1):39-48. PubMed ID: 19936724
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials for registration in the European Union: the EMEA 5-year experience in oncology.
Pignatti F; Aronsson B; Vamvakas S; Wade G; Papadouli I; Papaluca M; Moulon I; Le Courtois P
Crit Rev Oncol Hematol; 2002 May; 42(2):123-35. PubMed ID: 12007970
[TBL] [Abstract][Full Text] [Related]
15. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A
BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754
[TBL] [Abstract][Full Text] [Related]
16. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
Ainsworth MA
Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
[TBL] [Abstract][Full Text] [Related]
17. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
[TBL] [Abstract][Full Text] [Related]
18. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.
Apolone G; Joppi R; Bertele' V; Garattini S
Br J Cancer; 2005 Sep; 93(5):504-9. PubMed ID: 16136026
[TBL] [Abstract][Full Text] [Related]
19. Multistakeholder Advice at the European Medicines Agency: Is It Still Needed?
Vamvakas S; Moseley J; Vetter T
Clin Pharmacol Ther; 2019 Apr; 105(4):819-821. PubMed ID: 30811587
[No Abstract] [Full Text] [Related]
20. European Medicines Evaluation Agency and the new licensing arrangements.
Drug Ther Bull; 1994 Dec; 32(12):89-90. PubMed ID: 7635013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]